Non-feminizing estrogens: A novel neuroprotective therapy

Ashley B. Petrone, Joshua W. Gatson, James W. Simpkins, Miranda N. Reed

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

While the conflict between basic science evidence for estrogen neuroprotection and the lack of effectiveness in clinical trials is only now being resolved, it is clear that strategies for estrogen neuroprotection that avoid activation of ERs have the potential for clinical application. Herein we review the evidence from both in vitro and in vivo studies that describe high potency neuroprotection with non-feminizing estrogens. We have characterized many of the essential chemical features of non-feminizing estrogens that eliminate or reduce ER binding while maintaining or enhancing neuroprotection. Additionally, we provide evidence that these non-feminizing estrogens have efficacy in protecting the brain from AD neuropathology and traumatic brain injury. In conclusion, it appears that the non-feminizing estrogen strategy for neuroprotection is a viable option to achieve the beneficial neuroprotective effects of estrogens while eliminating the toxic off-target effects of chronic estrogen administration.

Original languageEnglish (US)
Pages (from-to)40-47
Number of pages8
JournalMolecular and Cellular Endocrinology
Volume389
Issue number1-2
DOIs
StatePublished - May 25 2014

Fingerprint

Estrogens
Therapeutics
Brain
Poisons
Neuroprotective Agents
Chemical activation
Neuroprotection
Clinical Trials

Keywords

  • Alzheimer's disease
  • Estradiol
  • Estrogen receptors
  • Neuroprotection
  • Non-feminizing estrogens
  • Traumatic brain injury

ASJC Scopus subject areas

  • Endocrinology
  • Molecular Biology
  • Biochemistry
  • Medicine(all)

Cite this

Non-feminizing estrogens : A novel neuroprotective therapy. / Petrone, Ashley B.; Gatson, Joshua W.; Simpkins, James W.; Reed, Miranda N.

In: Molecular and Cellular Endocrinology, Vol. 389, No. 1-2, 25.05.2014, p. 40-47.

Research output: Contribution to journalArticle

Petrone, Ashley B. ; Gatson, Joshua W. ; Simpkins, James W. ; Reed, Miranda N. / Non-feminizing estrogens : A novel neuroprotective therapy. In: Molecular and Cellular Endocrinology. 2014 ; Vol. 389, No. 1-2. pp. 40-47.
@article{0c402f33b334434bb0c82df274f85fd8,
title = "Non-feminizing estrogens: A novel neuroprotective therapy",
abstract = "While the conflict between basic science evidence for estrogen neuroprotection and the lack of effectiveness in clinical trials is only now being resolved, it is clear that strategies for estrogen neuroprotection that avoid activation of ERs have the potential for clinical application. Herein we review the evidence from both in vitro and in vivo studies that describe high potency neuroprotection with non-feminizing estrogens. We have characterized many of the essential chemical features of non-feminizing estrogens that eliminate or reduce ER binding while maintaining or enhancing neuroprotection. Additionally, we provide evidence that these non-feminizing estrogens have efficacy in protecting the brain from AD neuropathology and traumatic brain injury. In conclusion, it appears that the non-feminizing estrogen strategy for neuroprotection is a viable option to achieve the beneficial neuroprotective effects of estrogens while eliminating the toxic off-target effects of chronic estrogen administration.",
keywords = "Alzheimer's disease, Estradiol, Estrogen receptors, Neuroprotection, Non-feminizing estrogens, Traumatic brain injury",
author = "Petrone, {Ashley B.} and Gatson, {Joshua W.} and Simpkins, {James W.} and Reed, {Miranda N.}",
year = "2014",
month = "5",
day = "25",
doi = "10.1016/j.mce.2013.12.017",
language = "English (US)",
volume = "389",
pages = "40--47",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Non-feminizing estrogens

T2 - A novel neuroprotective therapy

AU - Petrone, Ashley B.

AU - Gatson, Joshua W.

AU - Simpkins, James W.

AU - Reed, Miranda N.

PY - 2014/5/25

Y1 - 2014/5/25

N2 - While the conflict between basic science evidence for estrogen neuroprotection and the lack of effectiveness in clinical trials is only now being resolved, it is clear that strategies for estrogen neuroprotection that avoid activation of ERs have the potential for clinical application. Herein we review the evidence from both in vitro and in vivo studies that describe high potency neuroprotection with non-feminizing estrogens. We have characterized many of the essential chemical features of non-feminizing estrogens that eliminate or reduce ER binding while maintaining or enhancing neuroprotection. Additionally, we provide evidence that these non-feminizing estrogens have efficacy in protecting the brain from AD neuropathology and traumatic brain injury. In conclusion, it appears that the non-feminizing estrogen strategy for neuroprotection is a viable option to achieve the beneficial neuroprotective effects of estrogens while eliminating the toxic off-target effects of chronic estrogen administration.

AB - While the conflict between basic science evidence for estrogen neuroprotection and the lack of effectiveness in clinical trials is only now being resolved, it is clear that strategies for estrogen neuroprotection that avoid activation of ERs have the potential for clinical application. Herein we review the evidence from both in vitro and in vivo studies that describe high potency neuroprotection with non-feminizing estrogens. We have characterized many of the essential chemical features of non-feminizing estrogens that eliminate or reduce ER binding while maintaining or enhancing neuroprotection. Additionally, we provide evidence that these non-feminizing estrogens have efficacy in protecting the brain from AD neuropathology and traumatic brain injury. In conclusion, it appears that the non-feminizing estrogen strategy for neuroprotection is a viable option to achieve the beneficial neuroprotective effects of estrogens while eliminating the toxic off-target effects of chronic estrogen administration.

KW - Alzheimer's disease

KW - Estradiol

KW - Estrogen receptors

KW - Neuroprotection

KW - Non-feminizing estrogens

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=84901491465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901491465&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2013.12.017

DO - 10.1016/j.mce.2013.12.017

M3 - Article

C2 - 24424441

AN - SCOPUS:84901491465

VL - 389

SP - 40

EP - 47

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - 1-2

ER -